UroGen Pharma Ltd (URGN)
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing therapies for urothelial and other specialty cancers. Its marketed products include Jelmyto for pyelocalyceal solutions, Zusduri, a sustained-release mitomycin formulation for non-muscle invasive bladder cancer, and RTGel, a proprietary biocompatible hydrogel platform designed for reverse thermal gelation. The company also has a generic mitomycin product used off-label in low-grade NMIBC in certain treatment settings.
UroGen’s pipeline includes UGN-103 and UGN-104, both in phase 3 development for intravesical and pyelocalyceal use, as well as UGN-301, UGN-301 plus UGN 201, and UGN-301 plus gemcitabine, which are in phase 1 studies for high-grade NMIBC. The company has licensing and supply arrangements with Agenus Inc. and medac Gesellschaft für klinische Spezialpräparate m.b.H. UroGen Pharma was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-URGN
|
$40.28
|
-5.7% Downside
|
Fair
|
$43.50
|
1.8% Upside
|
Fair
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-15.9x
|
-17.1x
|
15.1x
|
2.003 B
|
2.18 B
|
9.0%
|
88.7%
|
-2.2
|
—
|
124.6%
|
